ArticleThe Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
Oropouche fever cases in Salvador, Bahia, Brazil, 2024.
Article in The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOropouche Virus (OROV) is an arbovirus endemic to parts of Central and South America, historically confined to the Amazon region. In 2023‒2024, a significant expansion of OROV circulation was reported in Brazil, including autochthonous transmission in Salvador, Bahia. Despite its growing relevance, clinical descriptions are limited and mainly associated with the new lineage.
methodWe conducted a passive surveillance study based on medical records of patients confirmed by RT-qPCR for OROV infection who were treated at an Emergency Care Unit in Salvador, Bahia, between April and July 2024. Sociodemographic, clinical, and laboratory data were collected.
resultsWe collected information from 11 RT-PCR-confirmed patients with a mean age of 38-years, and a female predominance (55 %). The most prevalent symptoms were fever (100 %) and headache (100 %), myalgia (90 %), nausea (73 %), and arthralgia (55 %). No cases of severe or fatal outcomes were observed.
conclusionsThis study contributes to the clinical characterization of Oropouche fever in an emerging urban transmission setting outside the traditional endemic areas. The findings support the need for including OROV in the differential diagnosis of acute febrile illnesses, strengthening molecular surveillance, and expanding awareness among clinicians in non-Amazonian regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.